TY - JOUR
T1 - A Comparative Analysis of NOX4 Protein Expression in Malignant and Non-Malignant Thyroid Tumors
AU - Fenniche, Salma
AU - Oukabli, Mohamed
AU - Oubaddou, Yassire
AU - Chahdi, Hafsa
AU - Damiri, Amal
AU - Alghuzlan, Abir
AU - Laraqui, Abdelilah
AU - Dakka, Nadia
AU - Bakri, Youssef
AU - Dupuy, Corinne
AU - Ameziane El Hassani, Rabii
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/7/1
Y1 - 2023/7/1
N2 - The comparative analysis of the expression of the reactive oxygen species-generating NADPH oxidase NOX4 from TCGA data shows that the NOX4 transcript is upregulated in papillary thyroid carcinomas (PTC)-BRAFV600E tumors compared to PTC-BRAFwt tumors. However, a comparative analysis of NOX4 at the protein level in malignant and non-malignant tumors is missing. We explored NOX4 protein expression by immunohistochemistry staining in malignant tumors (28 classical forms of PTC (C-PTC), 17 follicular variants of PTC (F-PTC), and three anaplastic thyroid carcinomas (ATCs)) and in non-malignant tumors (six lymphocytic thyroiditis, four Graves’ disease, ten goiters, and 20 hyperplasias). We detected the BRAFV600E mutation by Sanger sequencing and digital droplet PCR. The results show that NOX4 was found to be higher (score ≥ 2) in C-PTC (92.9%) compared to F-PTC (52.9%) and ATC (33.3%) concerning malignant tumors. Interestingly, all C-PTC-BRAFV600E expressed a high score for NOX4 at the protein level, strengthening the positive correlation between the BRAFV600E mutation and NOX4 expression. In addition, independent of the mutational status of BRAF, we observed that 90% of C-PTC infiltrating tumors showed high NOX4 expression, suggesting that NOX4 may be considered a complementary biomarker in PTC aggressiveness. Interestingly, NOX4 was highly expressed in non-malignant thyroid diseases with different subcellular localizations.
AB - The comparative analysis of the expression of the reactive oxygen species-generating NADPH oxidase NOX4 from TCGA data shows that the NOX4 transcript is upregulated in papillary thyroid carcinomas (PTC)-BRAFV600E tumors compared to PTC-BRAFwt tumors. However, a comparative analysis of NOX4 at the protein level in malignant and non-malignant tumors is missing. We explored NOX4 protein expression by immunohistochemistry staining in malignant tumors (28 classical forms of PTC (C-PTC), 17 follicular variants of PTC (F-PTC), and three anaplastic thyroid carcinomas (ATCs)) and in non-malignant tumors (six lymphocytic thyroiditis, four Graves’ disease, ten goiters, and 20 hyperplasias). We detected the BRAFV600E mutation by Sanger sequencing and digital droplet PCR. The results show that NOX4 was found to be higher (score ≥ 2) in C-PTC (92.9%) compared to F-PTC (52.9%) and ATC (33.3%) concerning malignant tumors. Interestingly, all C-PTC-BRAFV600E expressed a high score for NOX4 at the protein level, strengthening the positive correlation between the BRAFV600E mutation and NOX4 expression. In addition, independent of the mutational status of BRAF, we observed that 90% of C-PTC infiltrating tumors showed high NOX4 expression, suggesting that NOX4 may be considered a complementary biomarker in PTC aggressiveness. Interestingly, NOX4 was highly expressed in non-malignant thyroid diseases with different subcellular localizations.
KW - biomarker
KW - BRAF hot spot mutation
KW - NADPH oxidase NOX4
KW - papillary thyroid carcinomas
UR - http://www.scopus.com/inward/record.url?scp=85165917539&partnerID=8YFLogxK
U2 - 10.3390/cimb45070367
DO - 10.3390/cimb45070367
M3 - Article
C2 - 37504283
AN - SCOPUS:85165917539
SN - 1467-3037
VL - 45
SP - 5811
EP - 5823
JO - Current Issues in Molecular Biology
JF - Current Issues in Molecular Biology
IS - 7
ER -